Burn Rate for Biotech Startups: Why It Looks Different Than SaaS
Table of Contents
Biotech startups burn cash at rates that would terrify a SaaS founder — and that is normal. Clinical trials, lab equipment, regulatory work, and specialized scientific staff add up to monthly burns of $500,000 to $5 million for early-stage companies, with zero revenue for years at a time.
This guide explains why biotech burn rate is structurally different, what the benchmarks look like, and how to track runway in an industry where the math is brutal but predictable.
Why Biotech Burns So Much More
A 10-person SaaS startup might burn $80,000 a month. A 10-person biotech burns $400,000-$800,000 because the cost structure is different:
- Specialized salaries: PhD scientists, regulatory affairs leads, and clinical operations staff command higher pay than software engineers
- Lab space and equipment: Wet labs cost $50-$150 per square foot per year, plus equipment that runs $50K-$500K per piece
- Clinical trials: A Phase 1 trial costs $1M-$5M; Phase 2 costs $5M-$25M; Phase 3 costs $25M-$300M+
- Manufacturing and supply: Producing drug candidates for trials requires CMO partnerships, cold storage, and quality systems
- Regulatory and IP: Patent filings, FDA submissions, legal compliance — all expensive and unavoidable
And during all of this, revenue is zero. Most biotech companies do not generate a dollar of product revenue until 7-12 years after founding. Burn rate is the only financial number that matters.
How Biotech Defines Runway
Biotech runway is measured the same way: cash divided by monthly burn. But the units are different. Where a SaaS founder thinks in months, biotech founders think in milestones.
"We have runway through Phase 1 readout" is more useful than "we have 18 months of runway." Both might be true, but the milestone framing is what investors actually care about. The question is not "when does the cash run out" but "what data do we have when it runs out, and is that data enough to raise the next round?"
Public biotech companies report runway in their quarterly filings. You can search any biotech ticker plus "cash runway" and find the number. Most public clinical-stage companies maintain 12-24 months of runway and update the number every quarter.
Sell Custom Apparel — We Handle Printing & Free ShippingTypical Biotech Burn Rates by Stage
| Stage | Typical Monthly Burn | Typical Round Size |
|---|---|---|
| Seed (pre-clinical) | $100K – $500K | $2M – $10M |
| Series A (pre-clinical or IND-enabling) | $500K – $2M | $15M – $50M |
| Series B (Phase 1) | $1M – $4M | $30M – $100M |
| Series C+ (Phase 2) | $3M – $10M+ | $50M – $200M+ |
These ranges vary wildly by therapeutic area, modality, and trial design. Cell and gene therapy companies run hot. Small molecule companies run leaner. Rare disease companies often raise less per round but burn faster per patient enrolled.
Tracking Burn Across Multiple Programs
Larger biotech companies track burn rate at the program level, not just the company level. Each drug candidate is its own cost center: research, preclinical, clinical, manufacturing, regulatory.
This is important because burn allocation drives portfolio decisions. If 70% of your burn is going to one program and 30% to another, prioritizing the right program is the difference between extending runway and extending it usefully.
The basic burn rate calculator at free burn rate calculator gives you the company-level number. For program-level allocation, use a spreadsheet or accounting tool that supports cost-center reporting.
The Public Comparable
Public biotech companies report cash and quarterly burn in every 10-Q filing. If you want to benchmark your burn rate against companies in your space, search for clinical-stage companies of similar size and look up their reported "cash runway" or "operating burn."
Common comparables founders cite: Adaptimmune, Allogene, Crinetics, Editas, Intellia, Moderna pre-IPO, Verastem, Viridian. Public reporting makes biotech burn rate one of the most transparent financial metrics in any industry.
Calculate Your Burn Rate
Free, fast, private. Works for any startup — biotech, SaaS, or anything in between.
Open Burn Rate CalculatorFrequently Asked Questions
Why do biotech VCs not seem worried about huge burn rates?
Because they expect it. Biotech VCs underwrite to clinical milestones, not to monthly P&L. The question they care about is "does this round give the company enough cash to reach a value-inflecting data readout?" If yes, the burn rate is acceptable; if no, the round needs to be bigger.
What is "operating cash runway" in biotech filings?
It is the same formula as basic runway but uses operating cash burn (excluding one-time financing activities, milestone payments, and other non-recurring items). Public biotech companies report this number quarterly to give investors a stable view of the operating trajectory.
Does the burn rate calculator work for biotech?
Yes — the math is identical regardless of industry. Plug in your cash, monthly operating expenses, and any monthly revenue (usually zero for biotech). The result tells you runway and zero date. Just be sure to use realistic numbers since biotech monthly burn can swing significantly with clinical milestones.